Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease

Gut

Volumn 65, Issue 3, 2016, Pages 415-425

  Quevrain E ^a,b,c   Maubert, M A ^a,b,c,d   Michon, C ^e   Chain, F ^e   Marquant, R ^a,c,f   Tailhades, J ^a,c,f   Miquel, S ^e   Carlier, L ^a,c,f   Bermudez Humaran L G ^e   Pigneur, B ^a,b,c   Lequin, O ^a,c,f   Kharrat, P ^e   Thomas, G ^a,b,c   Rainteau, D ^a,b,c,d   Aubry, C ^e   Breyner, N ^e   Afonso, C ^g   Lavielle, S ^a,c,f   Grill, J P ^a,b,c   Chassaing, G ^a,c,f   Chatel, J M ^e   Trugnan, G ^a,b,c,d   Xavier, R ^h   Langella, P ^e   Sokol, H ^a,b,c,d,e   Seksik, P ^a,b,c,d   more..

^a SORBONNE UNIVERSITÉ   (France)

^b Section of Radiology   (France)

^c CNRS   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e UMR1319 MICALIS   (France)

^f ECOLE NORMALE SUPÉRIEURE   (France)

^g UNIVERSITÉ DE ROUEN   (France)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYALANYVALYLTYROSYLASPARAGYLLEUCYLGLYCYLVALYLALANYPROLYLTHREONYLLYSYLASPARAGYLTHREONYLVALYLLYSYLGLUTAMYLTHREONYLGLUTAMYLVALYLLYSYLPHENYLALANYLTHREONYLVALINE; BACTERIAL PROTEIN; COMPLEMENTARY DNA; GLYCYLASPARAGYLTHREONYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLTHREONYLISOLEUCYLASPARAGYLARGINYLTHREONYLISOLEUCYLGLYCYLVALYLLEUCINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUCYLVALYLGLYCYLASPARAGYLTHREONYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLTHREONYLISOLEUCYLASPARAGYLARGINYLTHREONYLISOLEUCYLGLYCYLVALYLLEUCINE; MICROBIAL ANTI INFLAMMATORY MOLECULE PROTEIN; POLYPEPTIDE; THREONYLLEUCYLVALYLGLYCYLASPARAGYLTHREONYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLTHREONYLISOLEUCYLASPARAGYLARGINYLTHREONYLISOLEUCYLGLYCYLVALYLLEUCINE; UNCLASSIFIED DRUG; VALYLGLYCYLASPARAGYLTHREONYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLTHREONYLIASPARAGYLARGINYLTHREONYLISOLEUCYLGLYCYLVALYLLEUCINE; VALYLTHREONYLLEUCYLVALYLGLYCYLASPARAGYLTHREONYLPHENYLALANYLLEUCYLGLUTAMINYLSERYLTHREONYLISOLEUCYLASPARAGYLARGINYLTHREONYLISOLEUCYLGLYCYLVALYLLEUCINE; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CONCENTRATION (PARAMETERS); CROHN DISEASE; EMBRYO; FAECALIBACTERIUM PRAUSNITZII; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LACTOCOCCUS LACTIS; MASS SPECTROMETRY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; CLOSTRIDIALES; COLITIS; DYSBIOSIS; EVALUATION STUDY; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MALE; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MICROBIOLOGY; MOLECULAR GENETICS; PATHOLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL PROTEINS; BIOMARKERS; CELL LINE; CLOSTRIDIALES; COLITIS; CROHN DISEASE; DYSBIOSIS; HUMANS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NF-KAPPA B; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84960373289     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-307649     Document Type: Article

References (50)

1. MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J Gastroenterol 1996;31:907-16.
2. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
3. Allez M, Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm Bowel Dis 2004;10:666-76.
4. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
5. Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011;474:307-17.
6. Sokol H, Seksik P, Rigottier-Gois L, etal. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006;12:106-11.
7. Mukhopadhya I, Hansen R, El-Omar EM, etal. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-30.
8. Darfeuille-Michaud A, Boudeau J, Bulois P, etal. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004;127:412-21.
9. Man SM, Zhang L, Day AS, et al. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm Bowel Dis 2010;16:1008-16.
10. Kaakoush NO, Mitchell HM. Campylobacter concisus-a new player in intestinal disease. Front Cell Infect Microbiol 2012;2:4.
11. Bohr UR, Glasbrenner B, Primus A, et al. Identification of enterohepatic Helicobacter species in patients suffering from inflammatory bowel disease. J Clin Microbiol 2004;42:2766-8.
12. Man SM, Zhang L, Day AS, et al. Detection of enterohepatic and gastric helicobacter species in fecal specimens of children with Crohn's disease. Helicobacter 2008;13:234-8.
13. Sokol H, Seksik P, Furet JP, et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009;15:1183-9.
14. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008;105:16731-6.
15. Hansen R, Russell RK, Reiff C, et al. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am J Gastroenterol 2012;107:1913-22.
16. Zhang M, Qiu X, Zhang H, et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS ONE 2014;9:e109146.
17. Miquel S, Martin R, Rossi O, etal. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol 2013;16:255-61.
18. Martin R, Chain F, Miquel S, et al. The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm Bowel Dis 2014;20:417-30.
19. Wrzosek L, Miquel S, Noordine ML, etal. Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol 2013;11:61.
20. Miquel S, Leclerc M, Martin R, et al. Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio 2015;6:pii: e00300-15.
21. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol-Gastr L 2009;296:G1140-G49.
22. Vora P, Youdim A, Thomas LS, et al. beta-Defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004;173:5398-405.
23. Zyrek AA, Cichon C, Helms S, et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007;9:804-16.
24. Lecuyer E, Rakotobe S, Lengline-Garnier H, et al. Segmented filamentous bacterium uses secondary and tertiary lymphoid tissues to induce gut IgA and specific T helper 17 cell responses. Immunity 2014;40:608-20.
25. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009;31:677-89.
26. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009;139:485-98.
27. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011;331:337-41.
28. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009;9:313-23.
29. Schnupf P, Gaboriau-Routhiau V, Cerf-Bensussan N. Host interactions with Segmented Filamentous Bacteria: an unusual trade-off that drives the post-natal maturation of the gut immune system. Semin Immunol 2013;25:342-51.
30. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013;341:569-73.
31. Bouskra D, Brezillon C, Berard M, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008;456:507-10.
32. Yan F, Cao H, Cover TL, etal. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 2007;132:562-75.
33. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006;343:69-76.
34. Kelly D, Campbell JI, King TP, et al. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 2004;5:104-12.
35. Holo H, Nes IF. High-frequency transformation, by electroporation, of lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Appl Environ Microbiol 1989;55:3119-23.
36. Langella P, Le Loir Y, Ehrlich SD, et al. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. J Bacteriol 1993;175:5806-13.
37. Dieleman LA, Palmen MJHJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998;114:385-91.
38. Eswar N, Webb B, Marti-Renom MA, et al. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci 2007; Chapter 2:Unit 2 9. http://dx.doi.org/10.1002/0471140864
39. Whitney JC, Colvin KM, Marmont LS, et al. Structure of the cytoplasmic region of PelD, a degenerate diguanylate cyclase receptor that regulates exopolysaccharide production in Pseudomonas aeruginosa. J Biol Chem 2012;287:23582-93.
40. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005;308:1635-8.
41. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006;55:205-11.
42. Rajca S, Grondin V, Louis E, et al. Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. Inflamm Bowel Dis 2014;20:978-86.
43. Ryan RP. Cyclic di-GMP signalling and the regulation of bacterial virulence. Microbiology 2013;159:1286-97.
44. Sarrabayrouse G, Bossard C, Chauvin JM, et al. CD4CD8αα lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. PLoS Biol 2014;12:e1001833.
45. Hill DA, Artis D. Intestinal bacteria and the regulation of immune cell homeostasis. Annu Rev Immunol 2010;28:623-67.
46. Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013;500:232-6.
47. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-5.
48. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA 2010;107:12204-9.
49. Geuking MB, Cahenzli J, Lawson MA, et al. Intestinal bacterial colonization induces mutualistic regulatory T cell responses. Immunity 2011;34:794-806.
50. Kwon HK, Lee CG, So JS, et al. Generation of regulatory dendritic cells and CD4 (+) Foxp3 (+) T cells by probiotics administration suppresses immune disorders. P Natl Acad Sci USA 2010;107:2159-64.